Evidence map›Paper›PMID 34216312›Full record

ArticleCVIR endovascular2021

Aneurysmal degeneration of fluoropolymer-coated paclitaxel-eluting stent in the superficial femoral artery: a rising concern.

Takuya Tsujimura, Osamu Iida, Mitsutoshi Asai, Masaharu Masuda, Shin Okamoto, Takayuki Ishihara, Kiyonori Nanto, Takashi Kanda, Yasuhiro Matsuda, Yosuke Hata and 4 more

Open access · goldAbstract read
In one paragraph

Article in CVIR endovascular, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Takuya TsujimuraKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Osamu IidaKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan. iida.osa@gmail.com.
Mitsutoshi AsaiKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Masaharu MasudaKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Shin OkamotoKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Takayuki IshiharaKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Kiyonori NantoKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Takashi KandaKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Yasuhiro MatsudaKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Yosuke HataKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Hiroyuki UematsuKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Taku ToyoshimaKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Naoko HigashinoKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Toshiaki ManoKansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso Amagasaki, Hyogo, 660-8511, Japan.
Kansai Rosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough several clinical reports demonstrated a durable patency rate after a novel fluoropolymer-coated paclitaxel-eluting stent (Eluvia; Boston Scientific, Marlborough, MA, USA) placement, aneurysmal degeneration after drug-eluting stent (Eluvia) placement has raised clinical concerns. Here, we report a case with progressive aneurysm formation on serial angiography and intravascular ultrasound over 50 months after drug-eluting stent (Eluvia) placement for a superficial femoral artery atheromatous plaque. CASE PRESENTATION: A 79-year-old woman with right leg intermittent claudication at 100 m distance was referred to our hospital. Pre-procedural angiography showed long-segment severe stenosis from the middle-to-distal part of the right superficial femoral artery, and a 7 mm wide drug-eluting stent (Eluvia) was placed. However, the patient had a recurrence of intermittent claudication in the right lower extremity 25 months thereafter. Angiography revealed de novo stenosis in the distal part of the popliteal artery and proximal superficial femoral artery in-stent restenosis. Subsequently, the patient underwent endovascular therapy for these lesions. In addition, intravascular ultrasound at the time of endovascular therapy revealed femoral artery enlargement with a maximum vessel diameter of 10.0 mm at the distal edge of the stent. Intermittent claudication on the right side recurred again 50 months after drug-eluting stent (Eluvia). Angiography demonstrated de novo severe stenosis from the distal part of the superficial femoral artery to the middle part of the popliteal artery. Peri-stent contrast staining was found at the distal part of the drug-eluting stent (Eluvia) site. Intravascular ultrasound showed a further enlargement of maximum vessel diameter to 12.0 mm at the distal edge of the stent.

conclusionsWe report a case with progressive aneurysm degeneration on serial angiography and intravascular ultrasound over 50 months after drug-eluting stent (Eluvia) placement for a superficial femoral artery stenosis.

Indexed as

Aneurysmal degenerationEndovascular therapyFluoropolymer-coated paclitaxel-eluting stent

Identifiers

PMID34216312
PMCPMC8254708
OpenAlexW3174021904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.